Skip to main content

Personalized cardiopulmonary resuscitation device for emergency teams

Objective

Sudden cardiac arrest affects up to 1 million people in US and Europe per year, being the 3rd leading cause of death globally. Despite international medical efforts, 9 out of 10 people will die after a cardiac arrest (average survival rate 10.6%). In the European Union, cardiovascular disease costs to the economy more than €192 billion annually.
Emergency teams suffer the most with the extremely high mortality and morbidity rates due to cardiac arrest worldwide. Currently, medical assistive devices play a limited role on teams’ diagnostics and therapeutic actions during rescue emergencies. Nevertheless, the defibrillation/CPR devices global market was valued at $1.7B in 2014 and is expected to grow until 2019 with a CAGR of 8% reflecting a strong market demand.
pCPR is a portable, precise and personalized medical device to properly assist emergency teams during sudden cardiac arrest emergencies. It consists of a thoracic pad with sensors that doctors, nurses and paramedics apply directly to the patient linked to a new monitor display and defibrillator to support and guide their critical decision-making and patient-specific emergent therapy.
The value proposition of pCPR is based on emergency end-users’ feedback and experts’ calls for action, through a lean fast-to-market strategy, delivering unique selling points:
- Adaptive physiological feedback (disruptive innovation);
- Focus on cerebral oxygen saturation, temperature and tcCO2 (new target indicators);
- Clinical reasoning algorithms (cognitive aids at point of care);
- Cardiac/Neurologic outcomes guidance (assisting device);
- Data management for Quality control (analytics);
- Exclusively non-invasive sensors (technology);
pCPR wants to be one of the leading assistive device for emergency teams worldwide in a 5-years’ time frame, building upon its patented thoracic pad and combined sensing capabilities to deliver better cost-effective patient care and health outcomes, namely the cardiac arrest survival rate.

Call for proposal

H2020-SMEINST-1-2016-2017
See other projects for this call

Coordinator

MEDSIMLAB LDA
Address
Rue Alexandre Herculano 32 R/c Se Nova Santa Cruz Almedina E Sao Bartolomeu
3000 019 Coimbra
Portugal
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000